9 Results
February/March 2010
- Integration of Indications Discovery Efforts at Pfizer
Michael J. Barratt Ph.D., Senior Director & Technology Platform Lead, Indications Discovery Research Unit Donald E. Frail Ph.D, CSO, Indications Discovery Research Unit Pfizer Global Research and Development
- Flow Cytometry for Translational Applications: Multiparameter Analysis of Disaggregated Epithelial Tissues
Vera S. Donnenberg, Ph.D., Assistant Professor of Surgery and Pharmaceutical Sciences Albert D. Donnenberg, Ph.D., Professor of Medicine
- Ways to Expedite Acceptance of Emerging Biomarkers - From Bedside to Bench and Back: Validation of New Biomarkers in Animal Models and Patients
Frank Kramer, Ph.D., Research Scientist, Institute for Target Discovery / Biomarker, Bayer HealthCare AG
- Use of High Content Analysis in Toxicologic Clinical Pathology for Identification and Monitoring of Translational Safety Biomarkers
Peter O’Brien, DVM, PhD, DVSc Advanced Diagnostics Laboratory Staff Clinical Pathologist, Veterinary Hospital Director, Advanced Diagnostics Laboratory, NovaUCD University College of Dublin Margarida Canelas Domingos, Vet Med Clinical Pathology Resident, Veterinary Hospital University College Dublin
- Cell-Based Assays for GPCR Drug Discovery: Focus on Label-free
Lisa Minor, Ph.D. Vascular Research Team Johnson & Johnson PRD LLC
- Evaluation of Rat Reference Genes for Improved Quantitative Gene Expression Analysis
Jenny Hong Cai, MD, Medical Development Team, Emerging Market Business Unit Pfizer, Inc.
- Addressing Attrition in Early Drug Discovery by Label-Free Methodologies: Receptor Pharmacology in Native Cells
Julio Martin, Ph.D., Manager, Molecular Discovery Research Centro de Investigacion Basica, GlaxoSmithKline Isabel Coma, Investigator, Molecular Discovery Research Centro de Investigacion Basica, GlaxoSmithKline Magalie Rocheville, Ph.D., Research Investigator, Molecular Discovery Research, North Frontiers Science Park
- Real-time Quantitative PCR as a Bioanalytical Tool in the Pharmaceutical Industry
Jamie Murphy, Colorectal Fellow Stephen A. Bustin, Ph.D., Professor of Molecular Science Blizard Institute, Barts and the London School of Medicine and Dentistry Queen Mary, University of London
- The Changing Landscape for Stem Cells and Regenerative Medicine
Bernard Siegel, J.D. Executive Director Genetics Policy Institute